Acadia Pharmaceuticals Reports Third-Quarter Revenue of $342.29 Million, EPS of $0.31
Third-quarter revenue rose year over year as sales of NUPLAZID and DAYBUE grew. Earnings declined amid higher selling, general and administrative expenses, partly offset by lower research and development spending.
Acadia Pharmaceuticals’ third-quarter revenue rose year over year as unit sales grew for both NUPLAZID and DAYBUE products. Earnings declined, reflecting higher selling, general and administrative expenses, including expanded U.S. commercial teams, partly offset by lower research and development sp…